Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation

INTRODUCTION: It is essential to strengthen the treatment of latent tuberculosis infection (LTBI) to break the chain of transmission. The drug used worldwide for the treatment of LTBI is Isoniazid. A clinical trial conducted in Brazil has demonstrated the bioequivalence of Isoniazid in the 300 mg fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cola, João Paulo, do Prado, Thiago Nascimento, Campos, Bárbara Almeida, Borges, Bárbara Juliana Pinheiro, Alves, Bárbara Manuella Cardoso Sodré, de Jezus, Sonia Vivian, Sales, Carolina Maia Martins, de Araújo, Wildo Navegantes, Tavares, Noemia Urruth Leão, Noia Maciel, Ethel Leonor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942980/
https://www.ncbi.nlm.nih.gov/pubmed/36802383
http://dx.doi.org/10.1371/journal.pone.0281638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942980/
https://www.ncbi.nlm.nih.gov/pubmed/36802383
http://dx.doi.org/10.1371/journal.pone.0281638

Ejemplares similares